entertainment -WSS

entertainment

author：entertainment 2025-09-30 23:19:53 - browse：373

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： No plane should take off without an EpiPen onboard

hotspot

WSS

‘Oppenheimer’ and the risks of AI in health care

HHS leader on health, climate change and biopharma emissions

Eli Lilly expects to double planned employment in Boston center

‘Oppenheimer’ and the risks of AI in health care

EQRx, failed developer of low

STAT Summit: Michael J. Fox on progress in Parkinson's research

Wikipedia

entertainment

focus

23andMe had bad news about my health. I wish a person had delivered it

UnitedHealth’s board chair also owns a personal investment firm

Tori Bowie and the unacceptable rates of Black maternal death

STAT Summit: How a Chicago ER doctor tackles gun violence

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What to expect as Trump is arraigned on his Jan 6. indictment

Hollywood unions extend contract negotiations for actors

Solve the antibiotic resistance crisis with preventive drugs

Psychedelics group wrestles with new pharma identity

Trump indictment: Who are the 'co

leisure time

Impact of Dobbs ruling felt at reproductive medicine meeting

The explosion of genetic testing requires a new approach

‘Oppenheimer’ and the risks of AI in health care

First Opinion Podcast: Long Covid needs a new approach

NIH launches clinical trials and new research office for long Covid

FDA gives detailed accounting of AI

focus

knowledge

hotspot

focus